International Journal of Clinical Research

Objective Exploring the efficacy of Roxadustat capsules and recombinant human erythropoietin injection in treating anemia of hemodialysis patients. Methods Data from 40 patients undergoing long-term hemodialysis between June 2024 and December 2024 were collected as the control group (n=40, treated with recombinant human erythropoietin injection). Another 40 patients with similar conditions from January 2025 to June 2025 were collected as the observation group (n=40, treated with a combination of Roxadustat capsules and recombinant human erythropoietin injection). The clinical efficacy of both groups was compared. Results The observation group showed significantly better iron metabolism indicators, anemia-related indicators, and clinical treatment outcomes compared to the control group, with markedly lower inflammatory factor levels, all differences being statistically significant (P<0.05). There was no significant difference in adverse reaction rates between the two groups (P>0.05). Conclusion The combined use of Roxadustat capsules and recombinant human erythropoietin injection effectively improves iron metabolism and anemia-related indicators, reduces systemic inflammatory responses, and demonstrates higher safety with superior efficacy in treating anemia of hemodialysis patients.

Hemodialysis; Renal anemia; Roxadustat; Recombinant human erythropoietin